ABCs of cardiovascular disease risk management.
The past 20 years have witnessed a marked decline in morbidity and mortality from cardiovascular disease. This decline has been due in large part to advances in coronary risk factor modification and a better understanding of the atherosclerotic process. Compelling scientific and clinical trial evidence proves that comprehensive risk factor modification extends patient survival and reduces cardiovascular and cerebrovascular events. This article reviews the ABCs of optimal medical and lifestyle management in patients with documented atherosclerotic vascular disease as well as in those adults who are at increased risk for the development of cardiovascular disease, based on contemporary clinical trial evidence.
Braunstein
J B
JB
Ciccarone Center for Prevention of Heart Disease, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 538, Baltimore, MD 21205, USA.
Cheng
A
A
Fakhry
C
C
Nass
C M
CM
Vigilance
C
C
Blumenthal
R S
RS
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000628:therapy; D006801:Humans; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D016540:Smoking Cessation
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D008076:Cholesterol, HDL; D010975:Platelet Aggregation Inhibitors